CSL Ltd. - ADR
CSLLY
Market Cap$134.55B
Close$
Earnings Call Q4 2023
August 15, 2023 - AI Summary
CSL delivered strong full-year results, with revenue up 31% at constant currency and NPATA of $2.6 billion, up 20%.
The CSL Behring business saw strong growth in its Ig franchise, with sales up 21%. Plasma collections reached record levels, and the company dosed its first patients with HEMGENIX, a gene therapy for hemophilia B.
CSL Seqirus achieved strong sales growth, driven by FLUCELVAX, which was up 30%. The company also signed a licensing agreement with Arcturus Therapeutics for next-generation mRNA vaccine technology.
Exclusive for Stockcircle Pro members
Sign up
$31.98
53.3% downside
Current Fair Value
53.3% downsideOvervalued by 53.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $134.55 Billion |
|---|---|
| Enterprise Value | $144.99 Billion |
| Dividend Yield | $1.32 (2.00%) |
| Earnings per Share | $2.73 |
| Beta | 0.33 |
| Outstanding Shares | 971,912,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 21.62 |
|---|---|
| PEG | 387.68 |
| Price to Sales | 2.36 |
| Price to Book Ratio | 3.26 |
| Enterprise Value to Revenue | 4.98 |
| Enterprise Value to EBIT | 17.09 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About CSL Ltd.
CEO: Paul Perreault